GlassScriptPhysician profile
Patrick T Kobett
NPI 1376503896
$1,938.64
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $220 · 2021: $123 · 2022: $393 · 2023: $674 · 2024: $24.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306.15 | 2021-2023 | |
| Novo Nordisk INC | $224.36 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $187.63 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $168.10 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $123.77 | 2019-2023 | Xarelto |
| Pfizer INC. | $115.84 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.39 | 2020-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $82.39 | 2019-2020 | |
| Allergan, INC. | $69.84 | 2019-2020 | |
| Abbott Laboratories | $63.95 | 2019-2023 | Freestyle Libre |
| Teva Pharmaceuticals USA, INC. | $60.13 | 2019-2020 | |
| Amgen INC. | $58.34 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $56.40 | 2022-2023 | |
| Astellas Pharma US INC | $52.94 | 2019-2023 | Veozah |
| Dexcom, INC. | $35.89 | 2023 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.77 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.63 | 2020-2022 | |
| Insulet Corporation | $25.33 | 2022-2023 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $24.29 | 2022 | |
| Medtronic, INC. | $19.03 | 2022 | |
| Aytu Biopharma, INC. | $18.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.79 | 2022 | |
| Antares Pharma, INC. | $12.73 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.80 | 2021 | |
| Genentech USA, INC. | $11.77 | 2020 | |
| Merck Sharp & Dohme LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kobett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.